Biography
Professional Summary
Education & Certifications
- Fellowship: Stanford Hospital and Clinics Neuro-Oncology Fellowship CA
- Board Certification: American Board of Internal Medicine, Medical Oncology (2018)
- Fellowship: Loma Linda University Hematology and Medical Oncology Fellowship (2018) CA
-
- Residency: St Joseph Hospital Internal Medicine Residency (2010) IL
- Medical Education: MGM Medical College (2004) India
- Fellowship, Stanford University, Neuroendocrine Tumor Fellowship (2019)
- Fellowship, Loma Linda University, Hematology and Oncology Fellowship (2018)
- Residency, Saint Joseph University of Illinois at Chicago, Internal Medicine (2010)
- Internship, Government Medical College, Kashmir, Internship (2003)
- Medical Education, MGM Medical College, India, Bachelor of Medicine and Surgery (2002)
- Board Certification, American Board of Internal Medicine, Medical Oncology (2018)
- Board Certification, American Board of Internal Medicine, Internal Medicine (2010)
Publications
-
Concomitant KRAS and BRAF mutations in colorectal cancer
Midthun, L., Shaheen, S., Deisch, J., Senthil, M., Tsai, J., & Hsueh, C.-T. (2019). Concomitant KRAS and BRAF mutations in colorectal cancer. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 10(3), 577–81. -
Targeted and novel therapy in advanced gastric cancer
Selim, J. H., Shaheen, S., Sheu, W.-C., & Hsueh, C.-T. (2019). Targeted and novel therapy in advanced gastric cancer. EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 8(1), 25. -
Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature.
Shaheen, S., Mirshahidi, H., Nagaraj, G., & Hsueh, C.-T. T. (2018). Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature. Experimental Hematology & Oncology, 7, 11. -
-
Characterization of disease progression in ovarian cancer by utilizing 'chemograms' of ovarian cancer stem cells.
Guddati, A. K., & Shaheen, S. (2013). Characterization of disease progression in ovarian cancer by utilizing 'chemograms' of ovarian cancer stem cells. Journal of Chemotherapy (Florence, Italy), 25(3), 184–91. -
Gastrointestinal stromal tumor: a rare abdominal tumor.
Shaheen, S., & Guddati, A. K. (2013). Gastrointestinal stromal tumor: a rare abdominal tumor. Case Reports in Oncology, 6(1), 148–53. -
Uterine leiomyosarcoma manifesting as a tricuspid valve mass.
Marak, C. P., Ponea, A. M., Alappan, N., Shaheen, S., & Guddati, A. K. (2013). Uterine leiomyosarcoma manifesting as a tricuspid valve mass. Case Reports in Oncology, 6(1), 119–26. -
Extracavitary manifestation of primary effusion lymphoma as a right atrial mass.
Marak, C. P., Ponea, A. M., Shim, C., Shaheen, S., & Guddati, A. K. (2013). Extracavitary manifestation of primary effusion lymphoma as a right atrial mass. Case Reports in Oncology, 6(1), 114–8. -
Cutaneous metastasis of uterine adenocarcinoma: a case report and review of the literature.
Selim, A. A., Shaheen, S., Lockshin, N., & Khachemoune, A. (2009). Cutaneous metastasis of uterine adenocarcinoma: a case report and review of the literature. Cutis, 84(1), 33–8. -
Melanotic neuroectodermal tumor of infancy: review of literature and case report.
Selim, H., Shaheen, S., Barakat, K., & Selim, A. A. (2008). Melanotic neuroectodermal tumor of infancy: review of literature and case report. Journal of Pediatric Surgery, 43(6), E25–9. -
Secondary mucosa-associated lymphoid tissue (MALT) lymphoma of the colon.
Shaheen, S., & Guddati, A. K. (2013). Secondary mucosa-associated lymphoid tissue (MALT) lymphoma of the colon. Medical Oncology (Northwood, London, England), 30(2), 502. -
Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities.
Shaheen, S., Moradi, F., Gamino, G., & Kunz, P. L. (2020). Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities. Current Treatment Options in Oncology, 21(4), 25. -
Prevalence of Bone Metastases in Neuroendocrine Neoplasms by 68Ga DOTATATE PET Scan
Shaheen, S., Gardner, R., Sundaram, V., Hornbacker, K., Moradi, F., Wu, J., & Kunz, P. (2020). Prevalence of Bone Metastases in Neuroendocrine Neoplasms by 68Ga DOTATATE PET Scan. PANCREAS. LIPPINCOTT WILLIAMS & WILKINS. -
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Shah, M. H., Goldner, W. S., Benson, A. B., Bergsland, E., Blaszkowsky, L. S., Brock, P., … Hochstetler, C. (2021). Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 19(7), 839–868. -
Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up
Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Iagaru, A., & Aparici, C. M. (2022). Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up. ONCOLOGIST. -
Phase II trial of organ preservation program using short-course radiation and folfoxiri for rectal cancer (SHORT-FOX)
Pollom, E. L., Shelton, A., Fisher, G. A., Bien, J., King, D., Johnson, T. P., … Chang, D. T. (2022). Phase II trial of organ preservation program using short-course radiation and folfoxiri for rectal cancer (SHORT-FOX). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up.
Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Iagaru, A., & Mari Aparici, C. (2022). Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up. The Oncologist. -
Striking Size Reduction of Rapidly Growing Pancreatic Neuroendocrine Carcinoma Metastatic Nodal Conglomerate After Only 2 Cycles of 177Lu-DOTATATE.
Somoza, E. A., Duan, H., Shaheen, S., Fischer, G. A., & Aparici, C. M. (2022). Striking Size Reduction of Rapidly Growing Pancreatic Neuroendocrine Carcinoma Metastatic Nodal Conglomerate After Only 2 Cycles of 177Lu-DOTATATE. Clinical Nuclear Medicine. -
Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Pheochromocytoma and Paraganglioma From a Single Institution Experience
Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Moradi, F., … Aparici, C. M. (2022). Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Pheochromocytoma and Paraganglioma From a Single Institution Experience. PANCREAS. LIPPINCOTT WILLIAMS & WILKINS. -
Chromogranin A as surveillance biomarker in patients with carcinoids: CASPAR
Meng, Q., Halfdanarson, T. R., Bornhorst, J., Jann, H., Shaheen, S., Shi, R. Z., & Halperin, D. M. (2023). Chromogranin A as surveillance biomarker in patients with carcinoids: CASPAR. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX).
Pollom, E. L., Fisher, G. A., Shelton, A., Johnson, T. P., Chen, C., Jackson, S., … Chang, D. T. (2024). Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.
Chan, J. A., Geyer, S., Zemla, T., Knopp, M. V., Behr, S., Pulsipher, S., … Meyerhardt, J. A. (2024). Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. The New England Journal of Medicine. -
Circulating Chromogranin A as Surveillance Biomarker in Patients with Carcinoids - The CASPAR Study.
Meng, Q. H., Halfdanarson, T. R., Bornhorst, J. A., Jann, H., Shaheen, S., Shi, R. Z., … Halperin, D. M. (2024). Circulating Chromogranin A as Surveillance Biomarker in Patients with Carcinoids - The CASPAR Study. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Efficacy and safety of cabozantinib for advanced gastrointestinal (GI) neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of the phase 3 CABINET trial (Alliance A021602).
Strosberg, J. R., Zemla, T. J., Geyer, S. M., Knopp, M. V., Behr, S., Pulsipher, S., … Chan, J. A. (2025). Efficacy and safety of cabozantinib for advanced gastrointestinal (GI) neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of the phase 3 CABINET trial (Alliance A021602). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX): Two-Year primary outcome analysis.
Klebaner, D., Brown, E., Fisher, G. A., Shelton, A., Johnson, T. P., Shaheen, S., … Pollom, E. L. (2025). Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX): Two-Year primary outcome analysis. Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology, 207, 110884. -
Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy.
de Mestier, L., Halfdanarson, T. R., Apostolidis, L., Koumarianou, A., Hernando, J., Riechelmann, R., … Strosberg, J. R. (2025). Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy. Endocrine Pathology, 36(1), 42. -
Mammary small cell neuroendocrine carcinomas that showed excellent pathologic response following etoposide-based neoadjuvant chemotherapy.
Hammer, P. M., Enamandram, S., Ikeda, D. M., Lam, M. M., Wapnir, I. L., Chamberlain, E. D., … Bean, G. R. (2025). Mammary small cell neuroendocrine carcinomas that showed excellent pathologic response following etoposide-based neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 215(1), 10. -
First Autopsy-confirmed Complete Remission of Metastatic Neuroendocrine Neoplasm of Tailgut Cyst After a Single Cycle of Alpha-Peptide Receptor Radionuclide Therapy With [225Ac]Ac-DOTA-LM3.
Perrone, E., Shaheen, S., Kunz, P. L., Henri, H. C., & Baum, R. P. (2025). First Autopsy-confirmed Complete Remission of Metastatic Neuroendocrine Neoplasm of Tailgut Cyst After a Single Cycle of Alpha-Peptide Receptor Radionuclide Therapy With [225Ac]Ac-DOTA-LM3. Clinical Nuclear Medicine. -
Health-related quality of life (HRQOL) in the phase 3 trial of cabozantinib vs placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET, Alliance A021602).
Dueck, A. C., Fruth, B., Geyer, S. M., Zemla, T., Pulsipher, S., Ou, F.-S., … Chan, J. A. (2025). Health-related quality of life (HRQOL) in the phase 3 trial of cabozantinib vs placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET, Alliance A021602). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Carcinoid heart disease and urinary 5-HIAA in patients with pancreatic neuroendocrine tumors.
Paranjpe, I., Hornbacker, K., Vadde, S., & Shaheen, S. (2025). Carcinoid heart disease and urinary 5-HIAA in patients with pancreatic neuroendocrine tumors. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
-
Characterization of disease progression in ovarian cancer by utilizing 'chemograms' of ovarian cancer stem cells.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Phase II Pazopanib vs. Placebo in Progressive Carcinoid Tumors
- Chromogranin A as Surveillance Biomarker in Patients with cARcinoids
- Phase II Temozolomide or Temozolomide plus Capecitabine in Advanced Pancreatic NETs
- Phase II Platinum&Etoposide vs Temozolomide&Capecitabin in GastroenteropancreaticNeuroendocrinTumors
- Phase III Cabozantinib vs Placebo in Advanced Neuroendocrine Tumors After Progression on Everolimus
- Phase tbd Paltusotine Treatment in Carcinoid Syndrome
- Phase II Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic NETs
- Phase III 177Lu-DOTA0-Tyr3-Octreotate vs Octreotide LAR in Inoperable Midgut Carcinoid Tumours
Practice Locations
Gastrointestinal (GI) Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CAGastrointestinal (GI) Cancer Program in Palo Alto
875 Blake Wilbur Dr
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Review Summary
Dr. Shaheen is regarded as a kind and caring physician who listens attentively and explains information clearly. Many feel she is knowledgeable and thorough, inspiring confidence and providing a sense of peace of mind. Her communication is appreciated, especially in explaining complex results and coordinating with other healthcare providers.
The summary was created by AI, based on recent patient reviews. Learn more
Was this result useful to you?
Patient Reviews
(142 reviews)
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records